These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29257919)

  • 1. A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.
    Blum K; Han D; Modestino EJ; Saunders S; Roy AK; Jacobs W; Inaba DS; Baron D; Oscar-Berman M; Hauser M; Badgaiyan RD; Smith DE; Femino J; Gold MS
    Subst Use Misuse; 2018 Jan; 53(2):220-229. PubMed ID: 29257919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.
    Tzatzarakis MN; Vakonaki E; Kovatsi L; Belivanis S; Mantsi M; Alegakis A; Liesivuori J; Tsatsakis AM
    J Anal Toxicol; 2015 May; 39(4):313-20. PubMed ID: 25663675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorfine/Naloxone for the First Time in a Substance Treatment Unit.
    Mutlu C; Demirci AC; Yalcin O; Kilicoglu AG; Topal M; Karacetin G
    J Subst Abuse Treat; 2016 Aug; 67():1-8. PubMed ID: 27296655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction.
    Ransohoff JR; Petrides AK; Piscitello GJ; Flood JG; Melanson SEF
    Drug Alcohol Depend; 2019 Oct; 203():8-12. PubMed ID: 31394416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
    Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
    J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
    Dalton K; Butt N
    J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
    Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
    J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision.
    Elarabi HF; Hasan N; Marsden J; Radwan D; Adem A; Almamari S; Elrasheed A
    Pharmacopsychiatry; 2020 Apr; 53(3):115-121. PubMed ID: 32000269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
    Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
    Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.
    Monico LB; Gryczynski J; Schwartz RP; Jaffe JH; O'Grady KE; Mitchell SG
    Am J Drug Alcohol Abuse; 2018; 44(6):604-610. PubMed ID: 29718715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
    Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
    Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.
    Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder.
    Binger KJ; Ansara ED; Miles TM; Schulte SL
    Ment Health Clin; 2020 May; 10(3):80-84. PubMed ID: 32420004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine-naloxone therapy in pain management.
    Chen KY; Chen L; Mao J
    Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
    Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
    Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and experiences of buprenorphine-naloxone use among polysubstance users.
    Walker R; Logan TK; Chipley QT; Miller J
    Am J Drug Alcohol Abuse; 2018; 44(6):595-603. PubMed ID: 29693427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.